Literature DB >> 22672521

Left ventricular diastolic dysfunction in atrial fibrillation: predictors and relation with symptom severity.

Jedrzej Kosiuk1, Yves Van Belle, Kerstin Bode, Jelena Kornej, Arash Arya, Sascha Rolf, Daniela Husser, Gerhard Hindricks, Andreas Bollmann.   

Abstract

BACKGROUND: Left ventricular diastolic dysfunction (LVDD) is common in the general population, but its prevalence in atrial fibrillation (AF), predictors for LVDD in AF and the association between LVDD and AF-related symptom severity has not been well studied.
METHODS: In 124 consecutive patients (mean age 61 ± 11years, 60% male) with paroxysmal (n = 70) or persistent AF (n = 54) referred for AF catheter ablation, LVDD was evaluated according to current guidelines using transthoracic echocardiography. AF-related symptom severity was quantified using the European Heart Rhythm Association score.
RESULTS: LVDD was present in 46 patients (37%). In uni- and multivariable regression analysis, age (OR 1.068 per year, 95% CI 1.023-1.115, P = 0.003) and persistent AF (OR 2.427 vs. paroxysmal AF, 95% CI 1.112-5.3, P = 0.026) were associated with LVDD. LVDD was found in 11% with mild AF symptoms (n = 27) as opposed to 44% in patients with moderate-severe AF symptoms (n = 97, P = 0.002). Thus, the OR for moderate-severe AF symptoms was 6.368 (1.797-22.568, P = 0.004) in the presence of LVDD.
CONCLUSIONS: LVDD (1) occurs frequently in AF, (2) is associated with advancing age and AF progression and (3) is correlated with symptom severity in AF.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22672521     DOI: 10.1111/j.1540-8167.2012.02368.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  7 in total

Review 1.  [Patient selection for catheter ablation of atrial fibrillation: from paroxysmal to chronic].

Authors:  A Müssigbrodt; G Hindricks; P Sommer
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-03-14

2.  Recurrence of atrial fibrillation within three months after pulmonary vein isolation for patients with paroxysmal atrial fibrillation: Analysis using external loop recorder with auto-trigger function.

Authors:  Shiro Kawasaki; Kaoru Tanno; Akinori Ochi; Koichiro Inokuchi; Yuta Chiba; Yoshimi Onishi; Yoshimasa Onuma; Yumi Munetsugu; Miwa Kikuchi; Hiroyuki Ito; Tatsuya Onuki; Fumito Miyoshi; Yoshino Minoura; Norikazu Watanabe; Taro Adachi; Taku Asano; Youichi Kobayashi
Journal:  J Arrhythm       Date:  2014-09-20

3.  Atrial Fibrillation in Heart Failure Patients with Preserved or Reduced Ejection Fraction. Prognostic significance of Rhythm control strategy with Catheter Ablation.

Authors:  Nicolás Vecchio; Leonardo Ripa; Agustín Orosco; Leandro Tomas; Ignacio Mondragón; Adriana Acosta; Lujan Talavera; Santiago Rivera; Gastón Albina; Mirta Diez; Fernando Scazzuso
Journal:  J Atr Fibrillation       Date:  2019-02-28

4.  Relationship between exercise induced elevation of left ventricular filling pressure and exercise intolerance in patients with atrial fibrillation.

Authors:  Shao-Min Chen; Rong He; Wei-Hong Li; Zhao-Ping Li; Bao-Xia Chen; Xin-Heng Feng
Journal:  J Geriatr Cardiol       Date:  2016-09       Impact factor: 3.327

5.  Left Ventricular Diastolic Dysfunction as Predictor of Unfavorable Prognosis After ESUS.

Authors:  Agata Bielecka-Dabrowa; Paulina Gasiorek; Andrzej Wittczak; Agata Sakowicz; Ibadete Bytyçi; Maciej Banach
Journal:  J Multidiscip Healthc       Date:  2021-03-09

6.  Underweight is a major risk factor for atrial fibrillation in Asian people with type 2 diabetes mellitus.

Authors:  Jung-Chi Hsu; Yen-Yun Yang; Shu-Lin Chuang; Yi-Wei Chung; Chih-Hsien Wang; Lian-Yu Lin
Journal:  Cardiovasc Diabetol       Date:  2021-11-24       Impact factor: 9.951

7.  Anemia as an Independent Predictor of Adverse Cardiac Outcomes in Patients with Atrial Fibrillation.

Authors:  Wen-Hsien Lee; Po-Chao Hsu; Chun-Yuan Chu; Hung-Hao Lee; Meng-Kuang Lee; Chee-Siong Lee; Hsueh-Wei Yen; Tsung-Hsien Lin; Wen-Chol Voon; Wen-Ter Lai; Sheng-Hsiung Sheu; Ho-Ming Su
Journal:  Int J Med Sci       Date:  2015-07-16       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.